SOAT1 and asthma: Besides well-known omalizumab (Strunk and Bloomberg, 2006), mepolizumab (Ortega et al., 2014) and benralizumab (Nair et al., 2017), tofacitinib, a Janus kinase-signal transducers and activators of transcription (JAK-STAT) signal inhibitor, has exhibited anti-inflammatory effects in murine asthma models and represent the potential to be an effective treatment for asthma (Younis et al., 2019).